SCOPUS 정보 검색 플랫폼

Volumn 22, Issue 4, 2002, Pages 2317-2319

Fulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifen

(6) Bundred, Nigel J a Anderson, Elizabeth a Nicholson, Robert I a Dowsett, Mitchell a Dixon, Michael a Robertson, John F a

a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST (United Kingdom)

Author keywords

Apoptosis; Breast tumour; Cell turnover index; Fulvestrant; Proliferation; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; FULVESTRANT; PLACEBO; TAMOXIFEN;

APOPTOSIS; ARTICLE; BREAST TUMOR; CANCER INHIBITION; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HUMAN; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR DOWN REGULATION; TUMOR GROWTH;

EID: 0036331967 PISSN: 02507005 EISSN: None Source Type: Journal
DOI: None Document Type: Article

Times cited : (26)

References (13)

1
- 0035902115
- Proliferation, cell cycle and apoptosis in cancer
- (2001) Nature , vol.411 , pp. 342-348
- Evan, G.I.¹ Vousden, K.H.²

2
- 0034663421
- ICI 182,780 (Faslodex™): Development of a novel, "pure" antiestrogen
- (2000) Cancer , vol.89 , pp. 817-825
- Howell, A.¹ Osborne, C.K.² Morris, C.³ Wakeling, A.E.⁴

3
- 0026560435
- Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover
- (1992) Proc Natl Acad Sci USA , vol.89 , pp. 4037-4041
- Dauvois, S.¹ Danielian, P.S.² White, R.³ Parker, M.G.⁴

4
- 0026395885
- A potent specific pure antiestrogen with clinical potential
- (1991) Cancer Res , vol.51 , pp. 3867-3873
- Wakeling, A.E.¹ Dukes, M.² Bowler, J.³

5
- 0029075872
- Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer
- (1995) J Natl Cancer Inst , vol.87 , pp. 746-750
- Osborne, C.K.¹ Coronado-Heinsohn, E.B.² Hilsenbeck, S.G.³ McCue, B.L.⁴ Wakeling, A.E.⁵ McClelland, R.A.⁶ Manning, D.L.⁷ Nicholson, R.I.⁸

6
- 0027358687
- Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780
- (1993) Int J Cancer , vol.55 , pp. 873-876
- Hu, X.F.¹ Veroni, M.² De Luise, M.³ Wakeling, A.⁴ Sutherland, R.⁵ Watts, C.K.W.⁶ Zalcberg, J.R.⁷

7
- 0028861402
- Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer
- (1995) Lancet , vol.345 , pp. 29-30
- Howell, A.¹ DeFriend, D.J.² Robertson, J.F.³ Blamey, R.W.⁴ Walton, P.⁵

8
- 0002212877
- Comparison of efficacy and tolerability of fulvestrant (Faslodex™) with anastrozole (Arimidex™) in post-menopausal (PM) women with advanced breast cancer (ABC) - Preliminary results
- Abstract 6
- (2000) Breast Cancer Res Treat , vol.64 , pp. 27
- Howell, A.¹ Robertson, J.F.R.² Quaresma, A.J.³ Aschermannova, A.⁴ Mauriac, L.⁵ Kleeberg, U.R.⁶ Vergote, I.⁷ Erikstein, B.⁸ Webster, A.⁹ Morris, C.¹⁰

9
- 0000844647
- 'Faslodex' (ICI 182,780) shows longer duration of response compared with 'Arimidex' (anastrozole) in post-menopausal (PM) women with advanced breast cancer (ABC). Preliminary results of a phase III N. American trial
- Abstract 7
- (2001) Breast Cancer Res Treat , vol.65 , pp. 261
- Osborne, C.K.¹ Pippen, J.² Jones, S.E.³ Parker, L.M.⁴ Ellis, M.⁵ Come, S.⁶ Gertler, S.⁷ May, J.T.⁸ Burton, G.⁹ Webster, A.¹⁰ Morris, C.¹¹ Dimery, I.¹² Elledge, R.¹³ Buzdar, A.¹⁴

10
- 0009915823
- Comparison of the short-term biological effects of ICI 182,780 (Faslodex™) versus tamoxifen in postmenopausal women with primary breast cancer
- (2001) Cancer Res , vol.61 , pp. 6738-6746
- Robertson, J.F.¹ Nicholson, R.I.² Bundred, N.J.³ Anderson, E.⁴ Rayter, Z.⁵ Dowsett, M.⁶ Fox, J.N.⁷ Gee, J.M.W.⁸ Webster, A.⁹ Wakeling, A.E.¹⁰ Morris, C.¹¹ Dixon, M.¹²

11
- 0030874172
- Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer
- (1997) Int J Cancer , vol.72 , pp. 608-613
- Ellis, P.A.¹ Saccani-Jotti, G.² Clarke, R.³ Johnston, S.R.D.⁴ Anderson, E.⁵ Howell, A.⁶ A'Hern, R.⁷ Salter, J.⁸ Detre, S.⁹ Nicholson, R.¹⁰ Robertson, R.¹¹ Smith, I.E.¹² Dowsett, M.¹³

12
- 0034053157
- Effective tamoxifen therapy of breast cancer involves both antiproliferative and pro-apoptotic changes
- (2000) Eur J Cancer , vol.36 , pp. 845-851
- Cameron, D.A.¹ Keen, J.C.² Dixon, J.M.³ Bellamy, C.⁴ Hanby, A.⁵ Anderson, T.J.⁶ Miller, W.R.⁷

13
- 0006873070
- Comparison of the systemic and intratumural effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with breast cancer
- in press
- (2001) J Clin Oncol
- Harper-Wynne, C.L.¹ Sacks, N.P.M.² Shenton, K.³ McNeill, F.A.⁴ Sauven, P.⁵ Laidlaw, I.J.⁶

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.